MAP2K7 and pancreatic neoplasm: Intratumor genetic heterogeneity has also been shown to develop in response to MEK inhibitor delivery in pancreatic cancer cell lines and may contribute to the lackluster results of MEK inhibitor use in clinical trials for patients with advanced PAC [304].